Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMH5YQ3)

Drug Name

Sugemalimab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Approved in China	[1]
Extranodal NK/T-cell Lymphoma	2A90.6	Phase 3	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Non-small-cell lung cancer

ICD Disease Classification

2C25

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death 1 ligand 1 (PD-L1)	DTT	CD274	4.38E-07	0.37	2.1

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
2	ClinicalTrials.gov (NCT05700448) A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL). U.S.National Institutes of Health.
3	Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.